LYONS GARY A

Director Gary Lyons sold 15,000 NBIX shares at $152.61 on 2025-12-03; holds 120,482 shares post-transaction; stock near 52-week highs.

Gary Lyons sold 15,000 shares (11.1% of his pre-transaction holdings) at $152.61, with NBIX currently trading at $154.22, near its 52-week high of $154.80. His cross-ticker track record shows 3 prior sells with an average 90-day return of -3.4% and a 50.00% well-timed rate, indicating mixed historical timing on sales. At this specific ticker (NBIX), his prior two measurable sales resulted in divergent outcomes: a 2024-08-13 sale preceded a 90-day decline of -15.5%, while a 2024-05-14 sale preceded a 90-day gain of +8.6%. The company shows strong fundamentals with annual revenue growth of +24.8% and net income of $209,500,000.00 against quarterly revenue of $794,900,000.00, though the stock trades at a P/E of 35.95. This sale by a director should be monitored against NBIX's forward performance and Lyons' subsequent trading activity, though neither his historical track record nor his company-specific pattern provides a strong directional signal for this particular transaction.

Director Gary A. Lyons sold 11,570 shares of NBIX at $150.43 for $1,740,449.65 on 2024-08-13.

Gary A. Lyons, a director at Neurocrine Biosciences, sold 11,570 shares (11.6K shares) at $150.43, reducing his holdings from 130,617 to 119,047 shares, a -8.9% reduction in his position. The sale price of $150.43 was near the stock's 52-week high of $153.15, but the stock has since declined to $147.77 (-3.5% from the high), trading at a P/E of 43.98 against strong fundamentals including $590.2M quarterly revenue and +26.8% annual growth. Lyons' same-ticker history at NBIX shows 2 prior sells (on 2024-05-14 and 2023-12-22), neither well-timed at the 90-day mark, with post-sale returns of +0.5% and +5.6% respectively at 30 days, indicating the stock has typically risen after his prior sales at this ticker. The current sale occurs at a relatively elevated valuation and near historical highs, though without scheduled-trade documentation, the discretionary nature of the timing cannot be confirmed.